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Immunity
Previewsthe first time that part of the immunomod-
ulatory effects of helminth infection func-
tion via the microbiota, opening up the
possibility that live microbes or micro-
biota-derived products could be com-
bined with helminth products as addi-
tional therapeutic candidates. There is
no doubt that dissecting the multidirec-
tional interactions between parasites, the
microbiota, and the host immune system
is indeed challenging, but Zaiss et al.
(2015) have brought our attention to the
microbiota, which have now wormed
their way into our understanding of how
helminths manipulate the mammalian im-
mune system.842 Immunity 43, November 17, 2015 ª2015REFERENCES
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How immune tolerance is maintained in the skin remains unclear. In this issue of Immunity, Rosenblum and
colleagues demonstrate that tolerance to commensal bacteria is established during the neonatal period via
regulatory T cells. Defining the crucial window during which commensal-specific tolerance is achieved has
strategic implications for the induction of tolerance in allergic diseases.The skin is the outermost immunological
interface that harbors vast numbers of
resident leukocytes that provide surveil-
lance against pathogens while tolerating
millions of commensal microbes. The
important role of resident memory T cells
in conferring protective immunity in the
skin has been well recognized over the
last several years (Heath and Carbone,
2013). Meanwhile, pioneering micro-
biome studies have elucidated the land-
scape of the skin microbiota in health
and disease (Grice et al., 2009; Kong
et al., 2012), providing an impetus to
further explore the cross talk between
commensal bacteria and the immune sys-
tem. In the absence of skin commensals,
resident T cells in the skin are unable to
acquire proper effector states to exert
protective immunity against pathogens,
highlighting the importance of commen-sals in tuning skin immunity (Heath and
Carbone, 2013).
Regulatory T (Treg) cells are crucial for
the maintenance of systemic immune ho-
meostasis. Gastrointestinal Treg cells are
tuned by commensal bacteria to mediate
tolerance (Atarashi et al., 2011), and
mice that either have dysfunctional Treg
cells or lack them entirely spontaneously
develop inflammatory colitis (Ramsdell
and Ziegler, 2014). Given the abundance
of lymphocytes in the skin, it is reasonable
to hypothesize that a strict checkpoint
should exist for regulating excessive
immune responses—otherwise, lympho-
cytes would respond against commen-
sals, leading to uncontrolled skin inflam-
mation. The classic scurfy mouse
mutant, which has a FoxP3 mutation re-
sulting in impaired Treg cell differentiation
and severe skin inflammation, demon-strates that Treg cells are required for
the regulation of skin immune homeosta-
sis (Ramsdell and Ziegler, 2014). Whether
or not Treg cells are involved in inducing
tolerance against skin commensals and
thereby contribute to skin immune ho-
meostasis had not been previously
studied.
In this issue of Immunity, Scharschmidt
et al. develop a novel tool and an in vivo
assay to address the role of bacteria
in the induction of commensal-specific
Treg cells in the skin (Scharschmidt
et al., 2015). The authors’ utilization of
Staphylococcus epidermidis as a proto-
type is appropriate because S. epidermi-
dis is prevalent as a human commensal
and is also capable of colonizing mouse
skin. In this work, S. epidermidis is genet-
ically engineered to express the model
T cell antigen, 2W (Epi-2W), to enable
Figure 1. Commensal-Specific Tolerance Is Induced during the Neonatal Period
Colonization of adult mouse skin with Epi-2Wdoes not induce inflammation. When the pre-colonized adult
mice are then challenged with Epi-2W onto tape stripped skin at the indicated time point, skin inflam-
mation is induced (top panel). When the pre-colonization of Epi-2W is carried out during the neonatal
period (7 days after birth for 1 week), when a wave of Treg cell infiltration occurs in the skin, mice become
tolerant to Epi-2W challenge (middle panel). When the Treg cell infiltration is inhibited in neonatal skin via
FTY720, the achievement of Treg-cell-mediated tolerance is impaired and the mice display skin inflam-
mation upon Epi-2W challenge (bottom panel).
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Previewsthe measurement of antigen-specific
CD4+ T cell responses.
When Epi-2W was inoculated into adult
mice, it colonized the skin throughout the
1-week period that was studied. Despite
the lack of macroscopic or histological
evidence of inflammation, expansion of
2W-specific CD4+ T cells with an acti-
vated phenotype was detected in the
skin and in skin-draining lymph nodes,
as well as in the spleen. 2W-specific
CD4+ T cells were not detected in control
Epi-2W naive mice. To determine whether
pre-colonization of Epi-2W could induce
tolerance, adult mice were either un-
treated or colonized with Epi-2W for a
week. 2 to 4 weeks later, the skin of these
same mice was tape-stripped to remove
the upper layers of stratum corneum and
was challenged with Epi-2W. The authors
rationalized that the minor skin abrasion
created by tape stripping recapitulates
incidental minor trauma and that mecha-
nisms of immune tolerance against Epi-
2W would need to be active in this mild
inflammatory context. Epi-2W challenge
resulted in skin inflammation and activa-
tion of 2W-specific T cells in the skin andthe draining lymph nodes in both pre-
colonized and naive experimental groups
(Figure 1, top panel). Thus, Epi-2W pre-
colonization in adult mice fails to induce
tolerance against the S. epidermidis-
associated 2W antigen.
Because bacterial colonization of the
skin occurs early in life, the authors as-
sessed whether the neonatal period was
a preferred time frame for developing
tolerance against commensal bacteria.
Mice were colonized with Epi-2W on
postnatal day 7 for a week and were chal-
lenged, together with Epi-2W naive age-
matched animals, 3 to 4 weeks later.
Strikingly, and in contrast to the observa-
tion made in the adult mice, Epi-2W pre-
colonization during the neonatal period
resulted in attenuated skin inflammation
with decreased neutrophilic infiltration
and reduced numbers of activated 2W-
specific CD4+ T cells in the draining lymph
nodes (Figure 1, middle panel). Further-
more, analysis of Treg cells revealed
that Epi-2W pre-colonized mice had
increased numbers of 2W-specific CD4+
FoxP3+ Treg cells in both the skin and
skin-draining lymph nodes (Figure 1, mid-Immunity 43, Ndle panel). These data indicate that
neonatal exposure is required to achieve
tolerance againstS. epidermidis antigens.
The expansion of Epi-2W-specific Treg
cells strongly suggested their contributory
role in inducing commensal-specific
tolerance.
When the kinetics of Treg cells were
analyzed, the authors observed that an
abrupt wave of Treg cell skin infiltration
occurred from postnatal day 6 to 13.
These Treg cells expressed higher levels
of CTLA-4 and ICOS, both important me-
diators of Treg cell function, suggesting
that neonatal skin-infiltrating Treg cells
are highly active in their tolerizing capac-
ity. To prove that Treg cells were neces-
sary mediators of commensal-specific
immune tolerance, the authors blocked
the incoming wave of Treg cells into
neonatal skin with FTY720 (sphingosine-
1-phosphate receptor inhibitor; seques-
trates lymphocytes in the lymphoid
organs). The authors treated neonatal
mice with FTY720 or saline at days 5
and 7, immediately before the mice were
colonized with Epi-2W, then further chal-
lenged Epi-2W onto tape-stripped skin
4 weeks later (Figure 1, lower panel). In
contrast to mice that were Epi-2W pre-
colonized without FTY720, those pre-
colonized after FTY720 treatment ex-
hibited strong skin inflammation upon
challenge, with robust expansion of
2W-specific CD4+ non-Treg cells (likely
representing effector T cells) in the skin-
draining lymph nodes. Importantly, the
expansion of 2W-specific Treg cells was
impaired in both the skin and skin-drain-
ing lymph nodes (Figure 1, lower panel).
In aggregate, these data establish
that neonatal exposure to skin commen-
sals results in the generation of Treg cells
that are critical for mediating commensal-
specific tolerance. As the authors state, it
is important to determine in future studies
whether the tolerance induced during the
neonatal period has a lifelong effect. It
would be interesting to ask whether
neonatally-induced tolerance requires
continuous stimulus of the immune sys-
tem by the relevant commensal for it to
be maintained, and if so, it would be
important to address the cellular and
molecular mechanisms.
This work has strong therapeutic impli-
cations in the context of inflammatory skin
diseases, in particular for atopic derma-
titis (AD). The skin of AD-affected patientsovember 17, 2015 ª2015 Elsevier Inc. 843
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Previewsexhibits microbial dysbiosis, often domi-
nated by Staphylococcus aureus (Kong
et al., 2012). Although the role of
S. aureus in human AD still requires clari-
fication, its critical role in driving eczema
formation has recently been demon-
strated in an ADmousemodel (Kobayashi
et al., 2015). Although mutations in FLG,
encoding the skin-barrier protein filaggrin,
are strongly linked to the development of
AD, a confounding observation has been
that not everyone carrying this mutation
develops AD (Irvine et al., 2011). It is
intriguing to hypothesize that if genetically
predisposed individuals have the oppor-
tunity to establish S. aureus-specific
tolerance through exposure early in life,
they might not develop AD. Given that
not all healthy individuals are colonized
with S. aureus, it is also possible that
S. aureus-naive individuals might not
have acquired S. aureus-specific toler-
ance. Such a lack of tolerance could be
detrimental to those who are genetically
predisposed to AD.
This study’s gestalt agrees with a
recent finding on peanut allergy (Du Toit
et al., 2015). Whereas avoidance of aller-
gens had previously been the common
recommendation, this large cohort study
demonstrated that active consumption
of peanuts had beneficial effects on in-
fants with a peanut allergy. Although dis-
ease mechanisms could be distinct
between peanut allergy and AD, perhaps
early exposure to S. aureus in high-risk
patients could also be beneficial. This844 Immunity 43, November 17, 2015 ª2015concept must be accompanied by exten-
sive experimental evidence before being
tested in humans.
The ground-breaking discovery that
replacement of gut microbiota via fecal
transplant effectively treats Clostridium-
difficile-associated pseudomembranous
colitis has given momentum to the trans-
lational microbiome field (van Nood et al.,
2013). Fecal transplant therapy is also
being tested in inflammatory bowel dis-
ease (albeit with less successful results).
Given the prevalence of dysbiosis in AD
and the importance of S. aureus in the
AD model, one could imagine future
probiotic approaches or transplantation
of skin microbiota as new treatment
strategies in AD. However, as Scharsch-
midt et al. have shown, tolerance induc-
tion is an orchestrated event between
commensals and skin immunity that oc-
curs during the neonatal stage. Before
giant steps are taken to treat AD in
such a way, more human data must be
accumulated. Crucial questions include
(1) what is the critical window for induc-
tion of tolerance in humans and (2) is mi-
crobiota transplantation feasible after
that time frame? Once established, ac-
quired immunity is tough to overcome.
An individual might forever lose the op-
portunity to gain tolerance if they are
exposed to a given commensal or probi-
otic agent outside of the time frame dur-
ing which tolerance can be achieved.
The timing, as well as the cellular and
molecular mechanisms of commensal-Elsevier Inc.specific tolerance, is a theme that de-
serves further attention.
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